07108549-98ef-4c31-b649-feb043879304
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- ALLOGRAFT_REJECTION+0.300
- COAGULATION+0.300
- HEDGEHOG_SIGNALING+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- NOTCH_SIGNALING+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- ANGIOGENESIS+0.200
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MITOTIC_SPINDLE-0.400
- MTORC1_SIGNALING-0.400
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- CHOLESTEROL_HOMEOSTASIS-0.300
- MYC_TARGETS_V2-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- ADIPOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.905 |
| 2 | R52 | — | — | 0.899 |
| 3 | TCGA-AC-A3W6-01A-12R-A22K-07 | — | A | 0.898 |
| 4 | TCGA-E2-A1IJ-01A-11R-A144-07 | — | A | 0.897 |
| 5 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.893 |
| 6 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.892 |
| 7 | aMVAC.P_004_TURBT_S222 | — | — | 0.892 |
| 8 | ERR2278881 | — | — | 0.884 |
| 9 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.881 |
| 10 | BSR_03_0038_A2_S89 | — | A | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |